
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL Inc has seen a significant appreciation in its stock, with shares rising nearly 90% in the past month, indicating strong investor confidence. The company's positive outlook is supported by key developments, including encouraging data from the PATHFINDER 2 trial, a favorable proprietary Total Addressable Market (TAM) analysis revealing substantial opportunities in the US and UK, and established partnerships aimed at capitalizing on this potential. Additionally, GRAIL's financial position has been bolstered by over $400 million in pending funding, underscoring its strong market position in multi-cancer early detection technologies despite certain regulatory uncertainties.
Bears say
GRAIL Inc has sustained significant net losses since its inception and projects continued losses as it navigates regulatory challenges and expands its operational capacity. The company faces multiple risks, including legislative delays impacting reimbursement for its multi-cancer early detection tests, adoption barriers for its novel product, and intense competition from established diagnostics companies that possess greater resources. Additionally, rising selling, general, and administrative expenses, along with potential delays in clinical study results, pose substantial hurdles that could impede GRAIL's ability to successfully commercialize its offerings.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares